Equashield

Company Overview

Snapshot

Founded in April 2009 by Erik Shem Tov and Marino Kriheli, Equashield operates with 51–200 employees. The company was acquired by Nordic Capital in October 2022.

Business overview

Equashield Medical develops advanced, automated solutions designed to protect healthcare workers and facilities from hazardous drug exposure and contamination. The company's core products include Equashield CSTD, an airtight closed-system drug-transfer device, and Equashield Pro, an automatic compounding system utilizing image-processing algorithms. Equashield serves the healthcare industry, focusing on areas like pharmacy and oncology safety, and operates within the Health Tech & Life Sciences sector.

Strategic signal

In October 2022, Equashield was acquired by Nordic Capital, indicating a significant strategic validation and a new phase of growth under private equity ownership. This acquisition highlights the increasing investor interest in medical device companies that enhance safety and efficiency in healthcare, particularly in hazardous drug handling.

Company Intelligence Q&A

When was Equashield founded?

Equashield was founded in April 2009.

Who are the founders of Equashield?

Equashield was co-founded by Erik Shem Tov and Marino Kriheli.

What is Equashield's primary business?

Equashield develops closed-system transfer devices and automated compounding systems to protect healthcare workers from hazardous drug exposure.

What is the Equashield CSTD?

The Equashield CSTD is an airtight closed-system drug-transfer device designed to protect against occupational exposure to hazardous drugs.